The National Pharmaceutical Pricing Authority (NPPA) has fixed/revised ceiling prices of 24 scheduled formulations of Schedule-I under Drugs (Price Control) Amendment Order, 2016 and retail price of 31 formulations under DPCO, 2013 through a notification dated July 29, 2016.
Name of the scheduled formulations are doxycycline capsule, colchicine tablet, chlorpheniramine tablet, clofazimine capsule, ethambutol tablet, pyrazinamide tablet, fluconazole tablet lamivudine + zidovudine tablet, stavudine + lamivudine tablet, zidovudine tablet, chlorambucil tablet, cyclophosphamide tablet, melphalan tablet, diazepam tablet, metoclopramide tablet, glyceryl trinitrate sublingual tablet, atenolol tablet, ethinylestradiol tablet and acetazolamide tablet.
Retail price of scheduled formulations are teneligliptin +metformin HCl tablet, teneligliptin + metformin HCl tablet (Olymrpix M 500), teneligliptin + metformin HCl tablet (Tenepan M 500), teneligliptin + metformin HCl tablet (Tenglyn M 500), teneligliptin + metformin HCl tablet (Glytrin Met), paracetamol + caffeine+ phenylephrine HCl+ diphenhydramine HCl tablet (Zycold), paracetamol + caffeine+ phenylephrine HCl+ diphenhydramine HCl tablet (Nobel-Cold-New), paracetamol + caffeine+phenylephrine Hcl+ diphenhydramine HCl tablet (Noblok-New), paracetamol + caffeine+ phenylephrine HCl+diphenhydramine HCl tablet (Sumocold), pantoprazole tablet, paroxetine + clonazepam tablet (Depaxil CR Plus 12.5), paroxetine + clonazepam tablet (Depaxil CR Plus 25), diclonac injection, metformin HCl SR+ voglibose+ glimepiride tablet, metformin HCl SR+ voglibose+glimepiride tablet, ondansetron HCl spray (VOMI spray), rosuvastatin calcium +aspirin+ clopidogrel bisulphate tablet (Novastat Gold), teneligliptin + metformin HCl tablet, teneligliptin + metformin HCl tablet (Tenepride M 1000) teneligliptin + metformin HCl tablet (Afoglip M 1000), teneligliptin + metformin HCl tablet (Inogla M 1000), teneligliptin +metformin HCl tablet (Zilenta M Forte / J-Ring M Forte), teneligliptin + metformin HCl tablet (Olymrpix M 1000), teneligliptin + metformin HCl tablet and teneligliptin + metformin HCl tablet (TenePan M 1000).
Retail price is applicable only to the individual manufacturers/marketeers i.e. who have applied for the same by submitting Form-I for price fixation/revision as stipulated under DPCO, 2013 and subject to fulfillment of all the applicable statutory requirements as laid down by the government under relevant statutes/rules, including manufacturing license permission from the Competent Authority i.e. the Central/State Licensing Authority, as may be applicable, by the concerned manufacturers/marketing companies.
The concerned manufacturers of said formulations shall furnish quarterly return to the NPPA, in respect of production/import and sale of product in Form-III of Schedule-II of the DPCO, 2013 through IPDMS. Manufacturers in case intending to discontinue above said formulations, shall furnish information to the NPPA, in respect of discontinuation of the production and/or import of above said formulation in Form-IV of Schedule-II of the DPCO, 2013 at least six months prior to the intended date of discontinuation.
In case the retail price of any of the formulations is not complied with, as per instant price notification and notes specified, then the concerned manufacturer/marketing company shall be liable to deposit the overcharged amount along with the interest thereon under the provisions of the DPCO, 2013 read with the Essential Commodities Act, 1955.
Consequent to the issue of retail price of the formulations as specified in this notification, the price order(s) if any, issued for concerned manufacturer/marketeer prior to said date of notification, stand(s) superseded.